Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014144 · ClinicalTrials.gov registry record · Phase 2
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
A Phase 2 study of Bladder Cancer and Urethral Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 20
- Study locations
NCT00014144 is a Phase 2 study of Bladder Cancer and Urethral Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 31 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00014144, a Phase 2 study of Bladder Cancer and Urethral Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have advanced cancer of the urinary tract.
Conditions Studied
Interventions
- DRUG gefitinib
Study Locations (20)
California
- Cancer Center and Beckman Research Institute, City of Hope - Duarte
- Veterans Affairs Medical Center - Long Beach - Long Beach
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Veterans Affairs Medical Center - West Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Veterans Affairs Outpatient Clinic - Martinez - Martinez
- CCOP - Bay Area Tumor Institute - Oakland
- Chao Family Comprehensive Cancer Center - Orange
- University of California Davis Medical Center - Sacramento
- Veterans Affairs Medical Center - San Francisco - San Francisco
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
- David Grant Medical Center - Travis Air Force Base
Arizona
- CCOP - Greater Phoenix - Phoenix
- Veterans Affairs Medical Center - Phoenix (Hayden) - Phoenix
- Veterans Affairs Medical Center - Tucson - Tucson
- Arizona Cancer Center - Tucson
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
- MBCCOP - Gulf Coast - Mobile
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Veterans Affairs Medical Center - Little Rock (McClellan) - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2001-02 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014144
The ClinicalTrials.gov registry entry for NCT00014144 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which gefitinib is the first listed.
NCT00014144 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00014144 about?
NCT00014144 is a clinical study titled "S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract". RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have advanced cancer of the urinary tract.
What is the current status of trial NCT00014144?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2001-02. Estimated completion is 2007-12.
What conditions does trial NCT00014144 study?
This clinical trial studies the following conditions: Bladder Cancer, Urethral Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter.
What interventions are being tested in trial NCT00014144?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00014144?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00014144 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.